Structure Therapeutics Q1 Net Loss $(76.0)M; R&D Expenses Up 55%
Structure Therapeutics Inc. reported a net loss of $(76.0) million for Q1 2026, a significant increase from $(46.8) million in Q1 2025, driven by higher research and development and general and administrative expenses. Despite the increased loss, the company generated $15.2 million in net cash from operating activities, a notable improvement from a net cash outflow in the prior year. As of March 31, 2026, the company held $1.46 billion in cash, cash equivalents, and short-term investments, which it expects to fund operations for at least 12 months. The company also amended its ATM Sales Agreement in May 2026, increasing the aggregate offering price to $400.0 million, with $341.5 million remaining available.
Key Highlights
- Net loss for Q1 2026 was $(76.0) million, up from $(46.8) million in Q1 2025.
- Net loss per share was $(0.35) for Q1 2026, compared to $(0.27) in Q1 2025.
- Research and development expenses increased 55.1% to $66.5 million in Q1 2026.
- General and administrative expenses rose 70.1% to $22.9 million in Q1 2026.
- Net cash provided by operating activities was $15.2 million in Q1 2026, reversing a $(52.2) million outflow in Q1 2025.
- Cash, cash equivalents, and short-term investments totaled $1.46 billion as of March 31, 2026.
- ATM Sales Agreement amended in May 2026, increasing available shares by $150.0 million to $400.0 million.
- $341.5 million remained available for sale under the ATM Sales Agreement as of the filing date.
Price Impact
More from GPCR